Abdulla A. Damluji: Cardiovascular Outcomes with Tirzepatide Versus Dulaglutide in Type 2 Diabetes
Abdulla A. Damluji, Director of the Cardiovascular Center on Aging at Cleveland Clinic, has shared a post on X:
“Check out my latest article: Cardiovascular Outcomes with Tirzepatide Compared with Dulaglutide in Patients with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease via LinkedIn”
Title: Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes
Authors: Stephen J. Nicholls, Imre Pavo, Deepak L. Bhatt, John B. Buse, Stefano Del Prato, Steven E. Kahn, A. Michael Lincoff, Darren K. McGuire, Debra Miller, Michael A. Nauck, Hiroshi Nishiyama, Steven E. Nissen, Naveed Sattar, Govinda Weerakkody, Russell J. Wiese, Bernard Zinman, Sophia Zoungas, Jan Basile, Melanie J. Davies, Francesco Giorgino, Monika Kellerer, Linong Ji, Tamas Varkonyi, Venu Menon, Jonathan C. Broder, Alan Herschtal, David D’Alessio, Eli Lilly and Company, SURPASS-CVOT Investigators
Discover the latest in Hemostasis Today.
-
Sep 10, 2026, 10:53A New Era of Hemophilia Screening and Diagnosis in Women and Girls – ISTH
-
Sep 10, 2026, 10:03Investing in Youth, Transforming Hemophilia Care – WFH
-
Sep 10, 2026, 09:51Ronke Oke BEM: 20 Years of Newborn Sickle Cell Screening in England
-
Sep 10, 2026, 09:41Seunghwan Song: Hemlibra and the Science That Changed Hemophilia A Care
-
Sep 10, 2026, 09:20Mark Dawson: A Radical Rethink of Hemophilia Treatment
-
Sep 10, 2026, 07:26Carly Newton: Every Donation Helps Save Lives
-
Sep 10, 2026, 07:152023 ACR/EULAR APS Classification Criteria – APS Foundation of America
-
Sep 10, 2026, 07:03When Platelet Function Matters More Than Platelet Count – Glanzmann’s Research Foundation
-
Sep 10, 2026, 06:54Diego López Santos: Young Blood Donors Unite at the 23rd International Youth Forum in Tirana